Clinical trial of losartan potassium tablets combined with cyclophosphamide injection in the treatment of focal segmental glomerulosclerosis
10.13699/j.cnki.1001-6821.2019.07.009
- VernacularTitle:氯沙坦钾片联合环磷酰胺注射剂治疗局灶节段性肾小球硬化症的临床研究
- Author:
Li-Ping ZHAO
1
;
Lian-Sheng LIU
;
Gang HU
;
Mei-Liang LUO
;
Mei-Chun HUANG
;
Xiao-Qian YAN
;
Yu ZHONG
Author Information
1. 浙江省立同德医院 肾病科
- Keywords:
losartan potassium tablet;
cyclophosphamide injection;
focal segmental glomerulosclerosis;
safetyevaluation
- From:
The Chinese Journal of Clinical Pharmacology
2019;35(7):630-632
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of losartan potassium tablets combined with cyclophosphamide injection in the treatment of focal segmental glomerulosclerosis. Methods A total of90 patients of focal segmental glomerulosclerosis were randomly divided into control group (n = 41 cases) and treatment group (n = 49 cases) .Control group received cyclophosphamide 0. 6-1. 0 g per time, intravenous infusion, once every 3 to 4 weeks. Treatment group was given losartan potassium 50 mg per, orally in the morning, qd, on the basis of control group. Two groups were treated for 3 months. The clinical efficacy, renal function and adverse drug reactions were compared between two groups.Results After treatment, the total effective rates of treatment and control groups were 91. 84％ (45 cases/49 cases) and 73. 17％ (30 cases/41 cases) with significant difference (P < 0. 05) . After treatment, the main indexes of treatment and control groups were compared: urea nitrogen were (9. 37 ± 1. 55) and (10. 24 ± 1. 89) mmol · L-1, creatinine were (119. 95 ± 15. 51) and (138. 34 ± 15. 24) μmol · L-1, proteinquantitation were (0. 86 ± 0. 12) and (1. 33 ± 0. 18) g · 24 h-1, the differences were statistically significant (all P < 0. 05) . Adverse drug reactions of two groups were gastrointestinal reactions, elevated transaminase and bone marrow suppression. The total incidences of adverse drug reactions in the treatment and control groups were 18. 37％ and14. 63％ without significant difference (P> 0. 05) . Conclusion Losartan potassium tablets combined with cyclophosphamide injection have a definitive clinical efficacy in the treatment of focal segmental glomerulosclerosis, which can effectively control the proteinuria and improve the renal function, without increasing the incidence of adverse drug reactions.
